Wellell Valuation

Q: What is the Fair Price of 4106 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

4106 (NT$24.55) is trading above our estimate of [[fair value]] (NT$10.7)

Is 4106 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4106 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4106 (NT$24.55) is trading above our estimate of fair value (NT$10.7)

Significantly Below Fair Value: 4106 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4106?

Key metric: As 4106 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4106. This is calculated by dividing 4106's market cap by their current earnings.
What is 4106's PE Ratio?
PE Ratio	25.9x
Earnings	NT$95.66m
Market Cap	NT$2.48b

4106 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	9.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 4106's PE Ratio compare to its peers?

The above table shows the PE ratio for 4106 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.2x
6527 Crystalvue Medical	19.8x	n/a	NT$2.3b
1733 Apex Biotechnology	27.1x	n/a	NT$2.8b
4161 Bioptik Technology Incorporation	17.4x	n/a	NT$1.7b
6815 Diamond Biotechnology	36.6x	n/a	NT$2.5b
4106 Wellell	25.9x	n/a	NT$2.5b

Price-To-Earnings vs Peers: 4106 is expensive based on its Price-To-Earnings Ratio (25.9x) compared to the peer average (25.2x).

Price to Earnings Ratio vs Industry

How does 4106's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 4106 is expensive based on its Price-To-Earnings Ratio (25.9x) compared to the TW Medical Equipment industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is 4106's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4106 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	25.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4106's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Pacific Hospital Supply

NT$6.4b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$88.40

-0.5%

5.1%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

2.2%

Ma Kuang Healthcare Holding

NT$1.3b

An investment holding company, provides medical services in Taiwan and internationally.

4139

NT$29.85

-2.0%

-19.3%